

# IMMUNOGEN

ImmunoGen, Inc.  
Investor Relations Department  
830 Winter Street  
Waltham, MA 02451  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## NASDAQ: IMGN

Last Trade:	6.18
Trade Time:	4:00 PM ET Dec 11, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	1.53 - 8.84
Volume	N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology. The Company's lead product candidate, mirvetuximab soravtansine, is in a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in a Phase 1b/2 trial in combination regimens for earlier-stage disease. ImmunoGen has three additional clinical-stage product candidates, two of which are being developed in collaboration with Jazz Pharmaceuticals. ImmunoGen's ADC technology is also used in Roc... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

Dec 9, 2017

[ImmunoGen Presents New Clinical and Preclinical Data at ASH Annual Meeting](#)

Nov 7, 2017

[ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences](#)

Nov 3, 2017

[ImmunoGen Reports Recent Progress and Third Quarter 2017 Operating Results](#)

Nov 1, 2017

[ImmunoGen to Present New Data on Novel Antibody-Drug Conjugates at 59th ASH Annual Meeting](#)

Oct 20, 2017

[ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2017 Financial Results](#)

## Upcoming Events [\[ View all \]](#)

Jan 10, 2018 8:30 AM PT

[36th Annual J.P. Morgan Healthcare Conference Presentation](#)

Jan 10, 2018 12:00 PM PT

[36th Annual J.P. Morgan Healthcare Conference Q&A](#)

## Financials [\[ View all \]](#)

[Third Quarter Financial Results](#)

Apr 28, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 9, 2017

[Quarterly Report \(10-Q\)](#)

Aug 4, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)